2-(2-fluoro-ethyl)-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium bromide | 1023299-63-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(2-fluoro-ethyl)-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium bromide
• 英文别名: 2-(2-Fluoro-ethyl)-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium bromide；2-(2-fluoroethyl)-7,8-dihydro-6H-imidazo[1,5-c]pyrimidin-2-ium-5-one;bromide
• CAS: 1023299-63-9
• 化学式: Br*C₈H₁₁FN₃O
• 分子量: 264.097
• InChiKey: MKPIXEIGQCUDCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.14
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-fluoro-ethyl)-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium bromide 、 盐酸 反应 60.0h， 生成 2-[1-(2-Fluoro-ethyl)-1H-imidazol-4-yl]-ethylamine dihydrochloride
  参考文献：
  名称：

  5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors

  摘要：

  本发明涉及式Ia的化合物，其中：Ra *为氢或C1-C4-烷基；Rb *为-（C1-C4-烷基）-Y-C1-C4-卤代烷基或-（C1-C4-烷基）-Y-C1-C4-羟基烷基；Y代表-CONH-或五元杂环芳基基团。R2 *为C1-C4-烷基或卤素；R3 *为卤素，-SO2-CH3，-SO2-CF3，羧基，-CO-NH2，-CO-二（C1-C8-烷基）氨基，或具有氧，氮和硫的一种或多种环杂原子的5-或6-成员杂环环，该环可以被卤素，氰基，氧代，羟基，羧基，硝基，C3-C8-环烷基，C1-C8-烷基羰基，C1-C8-烷氧基可选择由氨基羰基取代，或C1-C8-烷基可选择由羟基，C1-C8-烷氧基，C1-C8-烷基氨基或二（C1-C8-烷基）氨基取代; R4 *为氢，卤素，-SO2-CH3，腈，C1-C8-卤代烷基，咪唑基，C1-C8-烷基，-NR8 * R9 *或-SO2-NR8 * R9 *; R5 *为氢，卤素或C1-C8-烷基；R8 *和R9 *分别为氢，氨基，C1-C8-烷基氨基，二（C1-C8-烷基）氨基，或CC1-C8-烷基可选择由羟基取代；或其药学上可接受的盐或溶剂，以及所述化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的用途。

  公开号：

  US07998990B2
• 作为产物：
  描述：

  5,6,7,8-四氢-5-氧代咪唑并[1,5-c]嘧啶 、 1-溴-2-氟乙烷 在 silica 、 methanol-dichloromethane 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 2-(2-fluoro-ethyl)-5-oxo-5,6,7,8-tetrahydro-imidazo[1,5-c]pyrimidin-2-ium bromide
  参考文献：
  名称：

  5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors

  摘要：

  本发明涉及式Ia的化合物，其中：Ra *为氢或C1-C4-烷基；Rb *为-（C1-C4-烷基）-Y-C1-C4-卤代烷基或-（C1-C4-烷基）-Y-C1-C4-羟基烷基；Y代表-CONH-或五元杂环芳基基团。R2 *为C1-C4-烷基或卤素；R3 *为卤素，-SO2-CH3，-SO2-CF3，羧基，-CO-NH2，-CO-二（C1-C8-烷基）氨基，或具有氧，氮和硫的一种或多种环杂原子的5-或6-成员杂环环，该环可以被卤素，氰基，氧代，羟基，羧基，硝基，C3-C8-环烷基，C1-C8-烷基羰基，C1-C8-烷氧基可选择由氨基羰基取代，或C1-C8-烷基可选择由羟基，C1-C8-烷氧基，C1-C8-烷基氨基或二（C1-C8-烷基）氨基取代; R4 *为氢，卤素，-SO2-CH3，腈，C1-C8-卤代烷基，咪唑基，C1-C8-烷基，-NR8 * R9 *或-SO2-NR8 * R9 *; R5 *为氢，卤素或C1-C8-烷基；R8 *和R9 *分别为氢，氨基，C1-C8-烷基氨基，二（C1-C8-烷基）氨基，或CC1-C8-烷基可选择由羟基取代；或其药学上可接受的盐或溶剂，以及所述化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的用途。

  公开号：

  US07998990B2

文献信息

• 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS
  申请人：Budd Emma

  公开号：US20090234132A1

  公开（公告）日：2009-09-17

  The present invention concerns a compound of formula Ia wherein: R a* is hydrogen or C 1-4 -alkyl; R b* is —(C 1 -C 4 -alkylene)-Y—C 1-4 -haloalkyl or —(C 1 -C 4 -alkylene)-Y—C 1 -C 4 -hydroxyalkyl; Y represents —CONH— or a five membered heteroaryl group. R 2* is C 1 -C 4 -alkyl or halogen; R 3* is halo, —SO 2 —CH 3 , —SO 2 —CF 3 , carboxy, —CO—NH 2 , —CO-di(C 1 -C 8 -alkyl)amino, or a 5- or 6-membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by halo, cyano, oxo, hydroxy, carboxy, nitro, C 3 -C 8 -cycloalkyl, C 1 -C 8 -alkylcarbonyl, C 1 -C 8 -alkoxy optionally substituted by aminocarbonyl, or C 1 -C 8 -alkyl optionally substituted by hydroxy, C 1 -C 8 -alkoxy, C 1 -C 8 -alkylamino or di(C 1 -C 8 -alkyl)amino; R 4* is hydrogen, halo, —SO 2 —CH 3 , nitrile, C 1 -C 8 -haloalkyl, imidazolyl, C 1 -C 8 -alkyl, —NR 8* R 9* , or —SO 2 —NR 8* R 9* ; and R 5* is hydrogen, halogen or C 1 -C 8 -alkyl; R 8* and R 9* are independently hydrogen, amino, C 1 -C 8 -alkylamino, di(C 1 -C 8 -alkyl)amino, or CC 1 -C 8 -alkyl optionally substituted by hydroxyl; or a pharmaceutically acceptable salt, or solvate thereof, to compositions and use of the compounds in the treatment of diseases ameliorated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及一种式Ia的化合物，其中：Ra*是氢或C1-4-烷基；Rb*是-（C1-C4-烷基）-Y-C1-4-卤代烷基或-（C1-C4-烷基）-Y-C1-C4-羟基烷基；Y代表-CONH-或五元杂环芳基基团。R2*是C1-C4-烷基或卤素；R3*是卤素，-SO2-CH3，-SO2-CF3，羧基，-CO-NH2，-CO-di（C1-C8-烷基）氨基，或具有一个或多个由氧、氮和硫组成的环异原子的5-或6元杂环，该环可以被卤素、氰基、氧代、羟基、羧基、硝基、C3-C8-环烷基、C1-C8-烷基羰基、C1-C8-烷氧基（可选择地被氨基羰基取代）、或C1-C8-烷基（可选择地被羟基、C1-C8-烷氧基、C1-C8-烷基氨基或二（C1-C8-烷基）氨基取代）取代；R4*是氢、卤素、-SO2-CH3、腈、C1-C8-卤代烷基、咪唑基、C1-C8-烷基、-NR8*R9*，或-SO2-NR8*R9*；R5*是氢、卤素或C1-C8-烷基；R8*和R9*独立地是氢、氨基、C1-C8-烷基氨基、二（C1-C8-烷基）氨基，或C1-C8-烷基（可选择地被羟基取代）；或其药学上可接受的盐或溶剂，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的组合物和用途。
• 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2029562A1

  公开（公告）日：2009-03-04
• US7998990B2
  申请人：——

  公开号：US7998990B2

  公开（公告）日：2011-08-16
• [EN] 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'URÉE 5-PHÉNYL-THIAZ0L-2-YL ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA KINASE PI3
  申请人：NOVARTIS AG

  公开号：WO2007134827A1

  公开（公告）日：2007-11-29

  [EN] The present invention concerns a compound of formula Ia wherein: R^{a *} is hydrogen or C₁-C₄-alkyl; R^b* is -(C₁-C₄-alkylene)-Y-C₁-C₄-haloalkyl or -(C₁-C₄-alkylene)-Y-C₁-C₄-hydroxyalkyl; Y represents -CONH- or a five membered heteroaryl group. R^2* is C₁-C₄-alkyl or halogen; R^3* is halo, -SO₂-CH₃, -SO₂-CF₃, carboxy, -CO-NH₂, -CO-di(C₁-C₈-alkyl)amino, or a 5- or 6- membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by halo, cyano, oxo, hydroxy, carboxy, nitro, C₃-C₈-cycloalkyl, C₁-C₈-alkylcarbonyl, C₁-C₈-alkoxy optionally substituted by aminocarbonyl, or C₁-C₈-alkyl optionally substituted by hydroxy, C₁- C₈-alkoxy, C₁- C₈-alkylamino or di(C₁- C₈-alkyl)amino; R^4* is hydrogen, halo, -SO₂-CH₃, nitrile, C₁- C₈-haloalkyl, imidazolyl, C₁- C₈-alkyl, -NR^8*R^9*, or -SO₂-NR^8*R^9*; and R^5* is hydrogen, halogen or C₁- C₈-alkyl; R^8* and R^9* are independently hydrogen, amino, C₁- C₈-alkylamino, di(C₁- C₈-alkyl)amino, or CC₁- C₈-alkyl optionally substituted by hydroxyl; or a pharmaceutically acceptable salt, or solvate thereof, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
  [FR] La présente invention concerne une composition de formule Ia dans laquelle : R^{a *} est de l'hydrogène ou de l'alkyle C₁-C₄; R^b* représente -(C₁-C₄-alkylène)-Y-C₁-C₄-haloalkyle ou -(C₁-C₄-alkylène)-Y-C₁-C₄-hydroxyalkyle; Y représente -CONH- ou un groupe d'hétéroaryle à cinq chaînons. R^2* représente alkyle C₁-C₄-ou halogène, R^3* représente halo, -SO₂-CH₃, -SO₂-CF₃, carboxy, -CO-NH₂, -CO-di(C₁-C₈-alkyl)amino, ou un anneau hétérocyclique à 5 ou 6 chaînons possédant un ou plusieurs hétéroatomes cycliques sélectionnés dans un groupe comprenant oxygène, azote et soufre, cet anneau étant éventuellement substitué par halo, cyano, oxo, hydroxy, carboxy, nitro, C₃-C₈-cycloalkyle, C₁-C₈-alkylcarbonyle, C₁-C₈-alkoxy substitué facultativement par aminocarbonyle, ou C₁-C₈-alkyle facultativement substitué par hydroxy, C₁- C₈-alkoxy, C₁- C₈-alkylamino ou di(C₁- C₈-alkyl)amino; R^4* représente hydrogène, halo, -SO₂-CH₃, nitrile, C₁- C₈-haloalkyle, imidazolyle, C₁- C₈-alkyle, -NR^8*R^9*, ou -SO₂-NR^8*R^9*; et R^5*représente hydrogène, halogène ou C₁- C₈-alkyle; R^8* et R^9* représentent indépendamment hydrogène, amino, C₁- C₈-alkylamino, di(C₁- C₈-alkyl)amino, ou CC₁- C₈-alkyle éventuellement substitués par hydroxyle, ou un sel pharmaceutiquement acceptable, ou un solvate dérivé, pour des compositions et l'utilisation de compositions dans le traitement de maladies amélioré par l'inhibition de la 3-kinase inositol phosphatidyle.
• 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors
  申请人：Novartis AG

  公开号：US07998990B2

  公开（公告）日：2011-08-16

  The present invention concerns a compound of formula Ia wherein: Ra* is hydrogen or C1-C4-alkyl; Rb* is —(C1-C4-alkylene)-Y—C1-C4-haloalkyl or —(C1-C4-alkylene)-Y—C1-C4-hydroxyalkyl; Y represents —CONH— or a five membered heteroaryl group. R2* is C1-C4-alkyl or halogen; R3* is halo, —SO2—CH3, —SO2—CF3, carboxy, —CO—NH2, —CO-di(C1-C8-alkyl)amino, or a 5- or 6-membered heterocyclic ring having one or more ring hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur, that ring being optionally substituted by halo, cyano, oxo, hydroxy, carboxy, nitro, C3-C8-cycloalkyl, C1-C8-alkylcarbonyl, C1-C8-alkoxy optionally substituted by aminocarbonyl, or C1-C8-alkyl optionally substituted by hydroxy, C1-C8-alkoxy, C1-C8-alkylamino or di(C1-C8-alkyl)amino; R4* is hydrogen, halo, —SO2—CH3, nitrile, C1-C8-haloalkyl, imidazolyl, C1-C8-alkyl, —NR8*R9*, or —SO2—NR8*R9*; and R5* is hydrogen, halogen or C1-C8-alkyl; R8* and R9* are independently hydrogen, amino, C1-C8-alkylamino, di(C1-C8-alkyl)amino, or CC1-C8-alkyl optionally substituted by hydroxyl; or a pharmaceutically acceptable salt, or solvate thereof, to compositions and use of the compounds in the treatment of diseases ameliorated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及式Ia的化合物，其中：Ra *为氢或C1-C4-烷基；Rb *为-（C1-C4-烷基）-Y-C1-C4-卤代烷基或-（C1-C4-烷基）-Y-C1-C4-羟基烷基；Y代表-CONH-或五元杂环芳基基团。R2 *为C1-C4-烷基或卤素；R3 *为卤素，-SO2-CH3，-SO2-CF3，羧基，-CO-NH2，-CO-二（C1-C8-烷基）氨基，或具有氧，氮和硫的一种或多种环杂原子的5-或6-成员杂环环，该环可以被卤素，氰基，氧代，羟基，羧基，硝基，C3-C8-环烷基，C1-C8-烷基羰基，C1-C8-烷氧基可选择由氨基羰基取代，或C1-C8-烷基可选择由羟基，C1-C8-烷氧基，C1-C8-烷基氨基或二（C1-C8-烷基）氨基取代; R4 *为氢，卤素，-SO2-CH3，腈，C1-C8-卤代烷基，咪唑基，C1-C8-烷基，-NR8 * R9 *或-SO2-NR8 * R9 *; R5 *为氢，卤素或C1-C8-烷基；R8 *和R9 *分别为氢，氨基，C1-C8-烷基氨基，二（C1-C8-烷基）氨基，或CC1-C8-烷基可选择由羟基取代；或其药学上可接受的盐或溶剂，以及所述化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的用途。